ANNX (Annexon) Price-to-Operating-Cash-Flow : (As of May. 29, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Annexon Price-to-Operating-Cash-Flow?

As of today (2025-05-29), Annexon's share price is $2.075. Annexon's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.96. Hence, Annexon's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Annexon's Price-to-Operating-Cash-Flow or its related term are showing as below:

ANNX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.23
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Annexon's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $-0.34. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.96.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 32.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 17.90% per year.

During the past 7 years, Annexon's highest 3-Year average Operating Cash Flow per Share Growth Rate was 32.30% per year. The lowest was -22.60% per year. And the median was 10.25% per year.

Annexon Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Annexon's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexon Price-to-Operating-Cash-Flow Chart

Annexon Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Annexon Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Annexon's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Annexon's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annexon's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexon's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Annexon's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Annexon Price-to-Operating-Cash-Flow Calculation

Annexon's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	2.075	/	-0.964
	=

Annexon's Share Price of today is $2.075.
Annexon's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.96.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Annexon Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Annexon's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Annexon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexon Inc (NAS:ANNX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005

Website

https://www.annexonbio.com

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Executives

Dean Richard Artis	officer: EVP & Chief Scientific Officer	C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005
Jennifer Lew	officer: EVP & Chief Financial Officer	2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Ted Yednock	officer: EVP & Chief Innovation Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg	officer: Chief Medical Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Overdorf	officer: EVP & Chief Business Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Douglas Love	director, officer: President & CEO	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William H. Carson	director	C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016
Muneer A Satter	director	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Bain Capital Life Sciences Fund, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bettina M. Cockroft	director	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Larry Mattheakis	officer: Chief Scientific Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Sanjay Keswani	officer: EVP & Chief Medical Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Clarus Lifesciences Iii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017